Butyrate: Potential role in colon cancer prevention and treatment

Advances in Experimental Medicine and Biology

Volumn 427, Issue , 1997, Pages 169-181

  Velázquez, Omaida C ^a   Rombeau, John L ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; BUTYRIC ACID; COMPACTIN; DEOXYCHOLIC ACID; MEVALONIC ACID; SODIUM CHLORIDE;

CELL PROLIFERATION; CELL VIABILITY; COLON CANCER; DIETARY INTAKE; DRUG MECHANISM; DRUG METABOLISM; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN TISSUE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0030709493     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-5967-2_18     Document Type: Review

References (65)

1. Angel P, Allegretto EA, Okino ST, et al, 1988, Oncongene Jun encodes a sequence-specific trans-activator similar to AP-1. Nature 332:166-171.
2. Bartram HP, Englert S, Scheppach W, et al, 1994, Antagonistic effects of deoxycholic acid and butyrate on epithelial cell proliferation in the proximal and distal human colon. Z Gastroenterol 32:389-392.
3. Bartram HP, Scheppach W, Schmid H, et al, 1993, Proliferation of human colonic mucosa as an intermediate biomarker of carcinogenesis: effects of butyrate, deoxycholate, calcium, ammonia, and pH. Cancer Res 53:3283-3288.
4. Bayerdorffer E, Mannes GA, Richter WO, et al, 1993, Increased serum deoxycholic acid levels in men with colorectal adenomas. Gastroenterology 104:145-151.
5. Boffa LC, Lupton JR, Mariani MR, et al, 1992, Modulation of colonic epithelial cell proliferation, histone acetylation, and luminal short chain fatty acids by variation of dietary fiber (wheat bran) in rats. Cancer Res 52:5906-5902.
6. Boring CC, Squires TS, Tong T., et al, 1994, Cancer statistics. CA Cancer J Clin;44(1):7-26.
7. Borner C, Fabbro D 1993, PKC and cellular transformation; in Protein kinase C, Lester DS, Epand RM (eds). Ellis Horwood, New York, pp 297-354.
8. Busch SJ, Sassone-Corsi P, 1990, Fos, Jun and CREB basic-domain peptides have intrinsic DNA-binding activity enhanced by a novel stabilizing factor. Trends Genet 6:36-40.
9. Chung YS, Song IS, Erickson RH, Sleisenger MH, Kim YS, 1985, Effect of growth and sodium butyrate on brush border membrane-associated hydrolases in human colorectal cancer cell lines. Cancer Res, 45:2976-82.
10. Colony PC, 1989, The identification of cell types in the normal adult colon. In Cell and molecular biology of colon cancer, LH Augenlicht (ed). Boca Raton, CRC Press, pp 2-21.
11. de Groot RP, Schoorlemmer J, Van Genesen ST, et al, 1990, Differential expression of Jun and Fos genes during differentiation of mouse P19 embryonal carcinoma cells. Nucleic Acids Res 18:3195-3202.
12. DeCosse JJ, Miller HH, Lesser ML 1989, Effect of wheat fiber and vitamins C and E on rectal polyps in patients with familial adenomatous polyposis. J Natl Cancer Inst; 81:1290-97.
13. Deng G, Liu G, Hu L, et al, 1992, Transcriptional regulation of the human placental-like alkaline phosphatase gene and mechanisms involved in its induction by sodium butyrate. Cancer Res 52:3378-3383.
14. DeRubertis FR, Craven PA, 1987, Relationship of bile salt stimulation of colonic epithelial phospholipid turnover and proliferative activity: role of activation of protein kinase C. Prev Med 16:572-579.
15. Deschner EE, Maskens AP, 1982, Significance of the labeling index and labeling distribution as kinetic parameters in colorectal mucosa of cancer patients and DMH treated animals. Cancer 50:1136-1141.
16. Folino M, McIntyre A, Young GP, 1995, Dietary fibers differ in their effects on large bowel epithelial proliferation and fecal fermentation-dependent events in rats. J Nutr 125:1521-1528.
17. lck associated with butyrate-induced differentiation of human colon carcinoma cells. Oncogene Res 5:13-23.
18. Freeman HJ, 1986, Effects of differing concentrations of sodium butyrate on 1,2-dimethlyhydrazine-induced rat intestinal neoplasia. Gastroenterology 91:596-602.
19. Goldrosen MH, 1980, Murine colon adenocarcinoma immunobiology of metastases. Cancer; 45:1223.
20. Gregg RG, Davidson M, Wilce PA. 1986. Cholesterol synthesis and HMG-CoA reductase activity during hepatocarcinogenesis in rats. Int J Biochem; 18:389-393.
21. Gutman M, Fidler IJ, 1995, Biology of human colon cancer metastases. World J Surg; 19:226-34.
22. Halazonetis TD, Georgopoulos K, Greenberg ME, et al, 1988, C-Jun dimerizes with itself and with c-Fos, forming complexes of different DNA binding affinities. Cell 55:917-924.
23. Hill MJ, Melville DM, Lennard-Jones JE, Ritchie JK, et al, 1987, Faecal bile acids, dysplasia, and carcinoma in ulcerative colitis. The Lancet July 25: 185-188.
24. Hill MJ, 1991, Bile acids and colorectal cancer: hypothesis. Eur J Cancer Prev 1(Supplement 2):69-72.
25. Howe GR, Benito E, Castelleto R, et al. 1992, Dietary intake of fiber and decreased risk of cancers of the colon and rectum: evidence from the combined analysis of 13 case-control studies. J Natl Cancer Inst 84:1887-1896.
26. Iwai SA, Kosaka M, Nishina Y, et al, 1993. Changes in Hox1.6. c-Jun, and Oct-3 gene expressions are associated with teratocarcinoma F9 cell differentiation in three different ways of induction. Experimental Cell Research 205:39-43.
27. Jacobs LR, 1983, Enhancement of rat colon carcinogenesis by wheat bran consumption during the stage of 1,2-dimthlhydrazine administration. Cancer Res 43:4057-4061.
28. Khosravi R, Cox AD, Kato K, Der CJ, 1992. Protein prenylation: key to ras function and cancer intervention? Cell Growth Differ; 3(7):461-69.
29. Kruh J, Tichonicky L, Defer N, 1994. Effect of butyrate on gene expression. In: Cummings J, Binder HJ, Soergel K, eds. Short-chain fatty acids. Boston, Kluwer Academic Publishers, 135-47.
30. h) labeling distribution as a marker for hereditary predisposition to colon cancer. Cancer Res 43:1899-1904.
31. Lipkin M, Enker W, Winawer SJ, 1987, Tritiated-thymidine labeling of rectal epithelial cells in "non-prep" biopsies of individuals at increase risk for colonic neoplasia. Cancer Lett 37:153-161.
32. Magrisso IJ, Richmond RE, Carter JH, et al, 1993, Immunohistochemical detection of RAS, JUN, FOS, and p53 oncoprotein expression in human colorectal adenomas and carcinomas. Laboratory Investigation 69:674-681.
33. Maltese WA, 1990, Posttranslational modification of proteins by isoprenoids in mammalian cells. FASEB J; 4:3319-3328.
34. McIntyre A, Gibson PR, Young GP, 1993, Butyrate production from dietary fibre and protection against large bowel cancer in a rat model. Gut; 34:386-91.
35. Miller AA, Kurschel E, Oseika R, Schmidt CG, 1987, Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur J Cancer Oncol; 23:1283-87.
36. Moertel CG, Fleming TR, MacDonald JS, et al, 1995, Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med; 122(5): 321-26.
37. Newmark HL, Lupton JR, Young CW, 1994, Butyrate as a differentiating agent: pharmacokinetics, analogues and current status. Cancer Lett; 78:1-5.
38. Nishina Y, Sumi T, Souichi A, et al, 1993, The induction of Jun genes during the reversible changes induced with sodium butyrate on the differentiation of F9 cells. Experimental Cell Research 208:492-497.
39. Otaka M, Singhal A, Hakomori S, 1989, Antibody-mediated targeting of differentiation inducers to tumor cells: inhibition of colonic cancer cell growth in vitro and in vivo. Biochem Biophys Res Commun; 158:202-8.
40. Pandey S, Gordon PH, Wang E, 1995, Expression of proliferation-specific genes in the mucosa adjacent to colon carcinoma. Dis Colon Rectum 38:462-467.
41. Perrin P, Cassagnau E, Burg C, et al, 1994, An interleukin 2/sodium butyrate combination as immunotherapy for rat colon cancer peritoneal carcinomatosis. Gastroenterology; 107: 1697-1708.
42. Rabizadeh E, Shaklai M, Nudelman A, et al, 1993, Rapid alteration of c-myc and c-Jun expression in leukemic cells induced to differentiate by a butyric acid prodrug. FEBS Lett 328:225-229.
43. Reddy BS, Engle A, Simi B, et al, 1992, Effect of dietary fiber on colonic bacterial enzymes and bile acids in relation to colon cancer. Gastroenterology 102:1475-1482.
44. Reddy BS, Weisburger JH, Wynder EL, 1978, Colon cancer: bile salts as tumor promoters; in carcinogenesis, Salga TJ, Sivak A, Boutwell RK (eds). Raven Press, New York, pp 453-464.
45. Roediger WE, 1994, The imprint of disease on short chain fatty acid metabolism by colonocytes. In: Binder HJ, Cummings J, Soergel K, eds. Short chain fatty acids. London: Kluwer Academic Publishers, 195-205.
46. Rombeau J, Kripke SA, Settle RG, 1990, Short-chain fatty acids: production, absorption, metabolism, and intestinal effects. In Dietary Fiber: Basic and Clinical Aspects, pp 317-339, New York, Plenum Press.
47. Schafer WR, Kim R, Sterne R, Thorner J, Kim S, Rine J, 1989, Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans. Science 245:379-85.
48. Scheele J, Stang R, Altendorf-Hofmann A, Paul M, 1995, Resection of colorectal liver metastases. World J Surg; 19:59-71.
49. Scheppach W, Bartram P, Richter A, et al, 1992 a, Effect of short-chain fatty acids on the human colonic mucosa in vitro. JPEN J Parenter Enter Nutr 16:43-48.
50. Scheppach W, Sommer H, Kirchner T, et al, 1992 b, Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology 103:51-56.
51. Souleimani A, Asselin C, 1993, Regulation of C-Fos expression by sodium butyrate in the human colon carcinoma cell line Caco-2. Biochem and Biophys Resch Commun 193(1):330-6.
52. Stoddart JH, Lane MA, Niles RN, 1989, Sodium butyrate suppresses the transforming activity of an activated N-ras oncogene in human colon carcinoma cells. Exp Cell Res 184:16-27.
53. Sugio K, Kurata S, Sasaki M, et al, 1988, Differential expression of c-myc gene and c-Fos gene in premalignant and malignant tissues from patients with familial polyposis coli. Cancer Res 48:4855-4861.
54. Tang SJ, Huang YM, Wang FF, 1995, Analysis of c-Fos expression in the butyrate-induced F-98 glioma cell differentiation. Biochem J 306:47-56.
55. Toscani A, Soprano DR, Soprano KJ, 1988, Molecular analysis of sodium butyrate-induced growth arrest. Oncogene Res 3:223-238.
56. Velázquez OC, Zhou D, Seto RW, Jabbar A, Choi J, Lederer HM, Rombeau JL, 1996 a,. In vivo crypt surface hyperproliferation is decreased by butyrate and increased by deoxycholate in normal rat colon. Associated in vivo effects on c-fos and c-jun expression. J Par Ent Nutr, in press.
57. Velázquez OC, Jabbar A, DeMatteo RP, Rombeau JL, 1996 b. Butyrate Inhibits Seeding and Growth of Colorectal Metastases to the Liver in Mice. Surgery, in press.
58. Velázquez OC, Lederer HM and Rombeau JL, 1996 c, Butyrate and the colonocyte: implications for neoplasia. Dig Dis and Sci, in press.
59. Wargovich MJ, Harris C, Chen C-D, et al, 1992. Growth kinetics and chemoprevention of aberrant crypts in the rat colon. J Cell Biochem. Supplement 16G:51-54.
60. Whitehead RH, Young GP, Bhathal PS, 1986, Effects of short chain fatty acids on a new human colon carcinoma cell line (LIM1215). Gut 27:1457-1463.
61. Yamaguchi-iwai Y, Satake M, Murakami Y, et al, 1990, Differentiation of F9 embryonal carcinoma cells induced by the c-Jun and activated c-Ha-ras oncogenes. Proc Natl Acad Sci USA 87:8670-8674.
62. Yang-yen H, Chiu R, Karin M, 1990, Elevation of AP-1 activate during F9 cell differentiation is due to increased c-Jun transcription. New Biologist 2:351-361.
63. Young GP, Gibson PR, 1994, Butyrate and colorectal cancer cell. In: Cummings J, Binder HJ, Soergel K, eds. Short-chain fatty acids. Boston: Kluwer Academic Publishers, 148-60.
64. Yu H, Harris RE, Gao YT, et al, 1990. Comparative epidemiology of cancers of the colon, rectum, prostate and breast in Shanghai, China versus the United States. Int J Epidemiol 20: 76-81.
65. Yu SG, Hildenbrandt LA, Elson CE, 1995, Geraniol, an inhibitor of mevalonate biosynthesis, suppresses the growth of hepatomas and melanomas transplanted to rats and mice. J Nutr; 125:2763-67.